AIM ImmunoTech Inc. (AIM)
AIMAMEXBiotechnology: Biological Products (No Diagnostic Substances)
$0.1599
+0.0049 (+3.16%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $6.45m
- P/E
- –
- EPS, last 4 quarters
- $-1.88
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1503 to $1.88
- Average volume
- 4.91m
- Previous close
- $0.1550
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $4.25, +2557.9% from here
Earnings
next estimate $-0.0900Next report Nov 16, 2026
Sep 2025
+67.3%
Dec 2025
+53.2%
Mar 2026
+36.1%
Jun 2026
-258.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $26.0k | $21.0k | $22.0k | $26.0k |
| Gross profit | -$42.0k | -$19.0k | $18.0k | $21.0k |
| Operating income | -$2.45m | -$2.95m | -$2.23m | -$3.51m |
| Net income | -$3.28m | -$4.17m | -$3.02m | -$3.79m |
Last four quarters: revenue $95.0k, margin -15021.0%, free cash flow –
News
8 latest- AIM ImmunoTech Inc. Highlights Ampligen Opportunity and 2027 MilestonesFintel · 4 days ago
- AIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral Potential RTTNews · Oct 5, 2026
- AIM ImmunoTech Advances Ampligen In Phase 2 Pancreatic Cancer Study RTTNews · Sep 9, 2026
- AIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares Jump RTTNews · Sep 3, 2026
- AIM ImmunoTech Secures Broad U.S. Patent For Ampligen In Combination With Keytruda; Stock Up RTTNews · Aug 31, 2026
- Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories RTTNews · Aug 29, 2026
- AIM ImmunoTech Reports Q2 Loss, Topline Phase 2 Pancreatic Cancer Data Due In Q1 2027 RTTNews · Aug 10, 2026
- AIM Doses Last Patient Early In Phase 2 DURIPANC For Ampligen In Treating Pancreatic Cancer RTTNews · Aug 4, 2026
The company
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.